1023971-89-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-6-fluoro-4-methylbenzonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow for the creation of complex organic compounds that can be further utilized in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-6-fluoro-4-methylbenzonitrile serves as a building block for the production of agrochemicals. Its chemical properties make it suitable for the synthesis of compounds that can be used in the development of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Synthesis:
2-Bromo-6-fluoro-4-methylbenzonitrile is utilized as a versatile intermediate in organic synthesis for the preparation of a wide range of organic compounds. Its ability to participate in various chemical reactions, such as nucleophilic substitution and palladium-catalyzed cross-coupling, makes it an essential component in the synthesis of complex organic molecules for various applications.

Upstream product

• 18349-09-2 2-bromo-6-fluoro-4-methyl aniline 
• 151-50-8 potassium cyanide 
• 452-80-2 2-fluoro-4-methylaniline 
• 1370025-54-9 2-bromo-6-fluoro-4-methylbenzaldehyde 
• 202865-83-6 1-bromo-3-fluoro-5-methylbenzene 

Relevant academic research and scientific papers

Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)

The C-5 substituted 2,4-diaminoquinazoline RG3039 (compound 1), a member of a chemical series that was identified and optimized using an SMN2 promoter screen, prolongs survival and improves motor function in a mouse model of spinal muscular atrophy (SMA).

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Synthesis of RHPS4 via an anionic ring closing cascade

A new and convergent synthesis of the potent telomerase inhibitor RHPS4 is presented. The key step is the construction of the pentacyclic framework via an anionic ring closing cascade in which two new rings are formed.